man playing guitar with granddaughter

Metastatic breast cancer patient benefits from clinical trial research

April 29, 2021 | Valerie Elwell
Alberta Bustamante is one of the first patients enrolled in cancer clinical trials under a new program at UCI Health to include people of from underrepresented Orange County communities.
Alberta Bustamante is one of the first patients enrolled in cancer clinical trials under a new program at UCI Health to include people from underrepresented Orange County communities.

Alberta Bustamante came to UCI Health in a wheelchair. The metastatic breast cancer patient is walking again thanks to an early-phase clinical trial funded by a National Cancer Institute (NCI) grant to boost enrollment of racial and ethnic minorities in such research.

For a variety of reasons — including economic and cultural — ethnic and racial minorities don’t get the latest and greatest care in general. They also are significantly underrepresented in clinical trials used to test emerging therapies and their effectiveness.

“Metastatic breast cancer trials have mostly involved Caucasians in this country,” says Dr. Ritesh Parajuli, who is Bustamante’s oncologist. “The data we gather when minority patients have not been enrolled might not be applicable to patients from ethnic and racial minorities.”

Addressing racial and ethnic disparities

Committed to ending these health disparities, the UCI Health Chao Family Comprehensive Cancer Center is using the NCI grant to enroll people like Bustamante and others among Orange County’s Asian, Black, Latino and other underserved communities in cancer therapy trials.

The cancer center received the prestigious award grant in August 2020 based on its previous success enrolling minority patients in clinical trials, the robust research infrastructure of its Stern Center for Cancer Clinical Trials & Research and its faculty’s expertise with early-phase clinical trials.

The $785,000 grant — Create Access to Targeted Cancer Therapy for Underserved Populations or CATCH-UP — enabled Parajuli to open a Phase 1 / 2 clinical trial to test a new metastatic cancer regimen and actively recruit minority participants. He invited Bustamante to enroll.

Access to leading-edge treatment

Like many patients, the Garden Grove woman was hesitant. But after discussions with her cancer team and son, Iker, who has been by her side throughout her long cancer journey, she agreed.

“I had already been through the worst with my initial breast cancer treatment,” she says. “I felt terrible then, but this seemed easier. I had a chance to feel a lot better. Why wouldn’t I give it a try?”

Bustamante was first diagnosed with stage II cancer in her left breast in 2008. She underwent a mastectomy, endured six months of chemotherapy and took tamoxifen, a hormone therapy that blocks estrogen, for eight years.

In 2016, she was involved in a car crash and was taken to UCI Medical Center, where X-rays and imaging scans showed a broken shoulder bone and the presence of cancer in her bones. She was advised to have her regular doctor check for a recurrence of her cancer but that didn’t happen.

Breast cancer returns

In 2018, Bustamante began having terrible lower back pain and stiffness. Soon she was having difficulty walking. But it wasn’t until August 2019 that her primary care doctor told her the breast cancer had returned and spread to her bones. By then, she could only get around with a wheelchair.

The physician referred Bustamante to Parajuli, who specializes specializes in breast cancer treatment. In December 2019, he started her on a standard-of-care treatment for metastatic breast cancer: a daily dose of ribociclib (an enzyme inhibitor that disrupts cancer cell growth) and injections of the estrogen-blocking drug fulvestrant every 28 days.

When she joined the clinical trial in November 2020, she got the investigational agent copanlisib, an enzyme inhibitor that may also limit tumor cell growth and delay progression of metastatic breast cancer, along with fulvestrant and the enzyme blocker abemaciclib.

From a wheelchair to walking

“After only eight weeks on the treatment, Alberta’s quality of life had significantly improved,” says Parajuli, assistant professor in the UCI School of Medicine’s Division of Hematology/Oncology and co-chair of the cancer center’s breast cancer disease team.

“Her back pain is greatly reduced. She’s sleeping well and has a good appetite. Her scans are showing no progression of the cancer in her bones and, best of all, she has greater mobility. She’s walking!”

Grateful to be able to get around on her own two feet again, Bustamante, 58, has this advice for cancer patients. “If you have the chance, join a clinical trial,” she says. “I feel so much better. You could, too.”

Related stories

Post a Comment

Your email address will not be displayed.
*